Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Laekna Therapeutics closes $18.5mm Series A round

Executive Summary

Laekna Therapeutics Shanghai Co. Ltd. (developing both small-molecule and antibody-targeted drugs for cancer and liver diseases) raised $18.5mm through a Series A round led by OrbiMed Asia, with AnlongMed also participating. The 2016 start-up plans to use the funding to progress its pipeline. Laekna currently has three oncology candidates, including Phase II LAE001 (CFG920), an oral CYP17 inhibitor for prostate cancer, in-licensed from Novartis last year. It is also developing compounds for liver diseases, including NASH and hepatic cirrhosis.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register